Editorial

Optimizing Vitamin K Antagonist Treatment in Patients with Mechanical Heart Valve Prosthesis

Vanessa Roldán[1]   Francisco Marín[2]

[1] Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
[2] Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, CIBER-CV, Universidad de Murcia, Murcia, Spain

Vitamin K antagonists (VKAs) have been the principal oral anticoagulation (OAC) option for the past 60 years. Although its management has much improved to optimize their efficacy and safety (and thus, patients outcomes), these drugs do still have important shortcomings. In spite of the development of non-VKA oral anticoagulants (NOACs), which offer a relative efficacy, safety and convenience compared with the VKAs, with fixed doses and less drug or diet interactions, there remain a huge number of patients who still use VKAs as their OAC of choice. These include patients with mechanical heart prosthesis and rheumatic valvular heart disease in association atrial fibrillation (AF).[1] Thus, all efforts should be directed to improve quality of anticoagulation control in these VKA users.

The most commonly used VKAs are 4-hydroxycoumarins derivatives, which included warfarin, phenprocoumon and acenocoumarol. Of these, phenprocoumon has the longest half-life and acenocoumarol has the shortest.[2] They exert an anticoagulant effect by interfering the synthesis of the vitamin K-dependent coagulation factors (factors II, VII, X and IX, and protein C, S and Z), leading to a decrease in the amount of reduced vitamin K required for the carboxylation of the vitamin K-dependent clotting factors.[3]

In general, the VKAs have major inter- and intra-individual variability and a narrow therapeutic range. This variability in the dose–response is influenced by several factors including drug interactions, dietary intake of vitamin K (especially nutritional supplements and herbal products), hepatic metabolism (and so dysfunction), renal dysfunction, alcohol intake and like other drugs, patient compliance.[4] Another important limitation is the slow onset and offset of action. These limitations make coagulation monitoring and frequent dose adjustments necessary to maintain the level of anticoagulation within therapeutic range to ensure efficacy and safety. Indeed, major bleeding and thrombotic complications are mainly related to the international normalized ratio (INR) levels out of range, age, comorbidities, polypharmacy and generally poor anticoagulation control, as reflected by time in therapeutic range (TTR).[2]

To date, we are perhaps able to explain up to 50% of variability in coumarin anticoagulants dose by knowing the following factor: age, ethnicity, comorbidities, concomitant medications and genetic patient profiles, mainly *VKORC1* and *CYP2C9*. However, pharmacogenetic dose adjustments have not been proven to be clinically beneficial.[5]

Laboratory anticoagulation monitoring for a patient taking VKA is made through the prothrombin time (which is sensitive to the decrease of factors II, VII and X) and is standardized thanks to the INR. The optimal target range for the INR is not the same for all indications, and bleeding is directly related to the intensity of anticoagulation.[6] In 1993, Rosendaal et al proposed a method to determine the optimal achieved intensity of anticoagulation (TTR) by the calculation of INR-specific incidence rates of adverse events (both thromboembolic or haemorrhagic) using a linear interpolation.[7]

In this issue of *Thrombosis and Haemostasis*, Gupta et al[8] report a systematic review and meta-analysis that evaluates the effect of a lower compared with higher INR target range on thrombotic and bleeding events, as well as mortality, in patients with mechanical heart valves. Along the time, the recommendations about the optimal INR range in patients with mechanical heart valves has been made with low or very low grades of evidence. Although, the authors recognize the low quality of data due to the high heterogeneity and the absence of standardization of variables and outcomes, this systematic review provides a good summary of the available data, and do not support the need of high INR target in patients with mechanical heart valves.

The intensity of anticoagulant therapy has been recognized as an important factor influencing the risk of bleeding.[3]

Address for correspondence
Vanessa Roldán, MD, PhD,
Servicio de Hematología y
Oncología Médica, Hospital
Universitario Morales Meseguer,
Avda de los Velez s/n,
Murcia 30008, Spain
(e-mail: vroldans@um.es).

However, most bleeding events occur within the therapeutic INR range (2.0–30)[9] and large INR fluctuations seem to be a more relevant risk factor given that a 'one off' random INR gives no indication of anticoagulation control.[10] Hence, the TTR or proportion of INRs in range (PINRR) are more important measures to determine the risks of bleeding and thromboembolism.[11] Notwithstanding some debates over the appropriateness of the method,[11,12] the Rosendaal method for calculating TTR remains widely used as a measure of the quality of anticoagulation control with the VKAs. Indeed, current guidelines recommend that we maintain a TTR of ∼65 to 70% to ensure an optimal treatment.[13] Patients who spent at least 70% of time within therapeutic range have a lower risk for stroke, bleeding and death,[14,15] although after adjusting for clinical variables, only bleeding risk remained significantly correlated with TTR.[16]

Recently, a retrospective, non-randomized multi-centre cohort study including all patients with mechanical heart valve prosthesis registered in the Swedish National Quality Registry Auricula from 2006 to 2011 showed that the highest rates of bleeding were seen in patients with high INR variability, low TTR and high treatment intensity.[17] Of these, among patients with mitral valve replacement and high TTR value, only age and previous bleeding were associated with the risk of bleeding.[18]

VKAs efficacy and safety has improved during the last years thanks to the standardization of the biological control (i.e. INR), the implementation of anticoagulation clinics, computerized dosage systems and self-management programs.[2,19] Health care providers who manage OAC therapy should incorporate patient education, systematic INR testing, tracking, follow-up and good patient communication of results and dosing decisions.[3] Indeed, patients are best managed in specialized anticoagulation clinics, which usually achieves higher values of TTR and generally provides the best outcomes.[19]

Conflict of Interest
None.

References

1 Lip GYH, Collet JP, de Caterina R, et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: executive summary of a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Thromb Haemost 2017;117(12):2215–2236

2 De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis–Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;110(06):1087–1107

3 Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2, Suppl):e44S–e88S

4 Esteve-Pastor MA, Rivera-Caravaca JM, Roldán-Rabadán I, et al; FANTASIIA Study Investigators. Relation of renal dysfunction to quality of anticoagulation control in patients with atrial fibrillation: the FANTASIIA Registry. Thromb Haemost 2018;118(02):279–287

5 Pérez-Andreu V, Roldán V, González-Conejero R, Hernández-Romero D, Vicente V, Marín F. Implications of pharmacogenetics for oral anticoagulants metabolism. Curr Drug Metab 2009;10(06):632–642

6 Keeling D, Baglin T, Tait C, et al; British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol 2011;154(03):311–324

7 Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69(03):236–239

8 Gupta S, Belley-Cote EP, Sarkaria A, et al. INR targets for left-sided mechanical valve replacement. A systematic review and meta-analysis. Thromb Haemost 2018;118(05). Doi: 10.1055/s-0038-1637755

9 Pourgholi L, Goodarzynejad H, Mandegary A, et al. Gene polymorphisms and the risk of warfarin-induced bleeding complications at therapeutic international normalized ratio (INR). Toxicol Appl Pharmacol 2016;309:37–43

10 Ibrahim S, Jespersen J, Poller L; European Action on Anticoagulation. The clinical evaluation of international normalized ratio variability and control in conventional oral anticoagulant administration by use of the variance growth rate. J Thromb Haemost 2013;11(08):1540–1546

11 Rosendaal FR, Cannegieter SC. Control of anticoagulation with VKAs: overestimation of median TTR when assessed by linear extrapolation: a comment. Thromb Haemost 2017;117(04):819

12 van den Besselaar AMHP, Biedermann JS, van der Meer FJM, Adriaansen HJ, Leebeek FWG, Kruip MJHA. Control of anticoagulation with vitamin K antagonists: overestimation of median time in therapeutic range when assessed by linear interpolation. Thromb Haemost 2016;116(04):679–686

13 Kirchhof P, Benussi S, Kotecha D, et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37(38):2893–2962

14 Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011;106(05):968–977

15 Van Den Ham HA, Klungel OH, Leufkens HG, Van Staa TP. The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation. J Thromb Haemost 2013;11(01):107–115

16 Vestergaard AS, Skjøth F, Larsen TB, Ehlers LH. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: a systematic review and meta-regression analysis. PLoS One 2017;12(11):e0188482

17 Grzymala-Lubanski B, Svensson PJ, Renlund H, Jeppsson A, Själander A. Warfarin treatment quality and prognosis in patients with mechanical heart valve prosthesis. Heart 2017;103(03):198–203

18 Labaf A, Svensson PJ, Renlund H, Jeppsson A, Själander A. Incidence and risk factors for thromboembolism and major bleeding in patients with mechanical valve prosthesis: a nationwide population-based study. Am Heart J 2016;181:1–9

19 Roldán V, Marín F. The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists. Thromb Haemost 2015;113(04):671–673